UroGen Pharma: Patient dosed in mitomycin-based UGN-103 trial for LG-IR-NMIBC
PremiumThe FlyUroGen Pharma: Patient dosed in mitomycin-based UGN-103 trial for LG-IR-NMIBC
1M ago
UroGen Pharma receives new U.S. patent allowance for RTGel technology
Premium
The Fly
UroGen Pharma receives new U.S. patent allowance for RTGel technology
2M ago
UroGen Pharma management to meet with Oppenheimer
Premium
The Fly
UroGen Pharma management to meet with Oppenheimer
2M ago
Is URGN a Buy, Before Earnings?
PremiumPre-EarningsIs URGN a Buy, Before Earnings?
3M ago
UroGen Pharma Shareholders Shape Governance and Incentives
Premium
Company Announcements
UroGen Pharma Shareholders Shape Governance and Incentives
3M ago
UroGen Pharma 5M share Spot Secondary priced at $17.50
Premium
The Fly
UroGen Pharma 5M share Spot Secondary priced at $17.50
5M ago
UroGen Pharma price target raised to $60 from $54 at H.C. Wainwright
PremiumThe FlyUroGen Pharma price target raised to $60 from $54 at H.C. Wainwright
5M ago
UroGen Pharma trading resumes
Premium
The Fly
UroGen Pharma trading resumes
5M ago
UroGen Pharma’s Promising Trial Results and FDA Progress
Premium
Company Announcements
UroGen Pharma’s Promising Trial Results and FDA Progress
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100